Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DTIL | PRECISION BIOSCIENCES INC | 2026-04-02 15:10:04 | 5.82 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DTIL | 0001357874 | PRECISION BIOSCIENCES INC | US74019P2074 | 549300I5QGRS3BLHZH41 | — | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 302 EAST PETTIGREW STREET | DURHAM | NC | 27701 | UNITED STATES | US | 919-314-5512 | 302 EAST PETTIGREW STREET, DURHAM, NC, 27701 | 302 EAST PETTIGREW STREET, DURHAM, NC, 27701 | — | Biotechnology | 2006 | Michael Amoroso | 192 | http://precisionbiosciences.com | 47,100,000 | 24,115,346 | 24,726,695 | Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. | 2026-04-02 19:07:32 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 47,100,000 | -19,700,000 | -29.491 | 24,726,695 | 14,244,764 | 135.8983 |
| 2024 | 66,800,000 | 7,700,000 | 13.0288 | 10,481,931 | 3,565,692 | 51.5554 |
| 2023 | 59,100,000 | -111,200,000 | -65.2965 | 6,916,239 | -104,379,484 | -93.7857 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Alex Kelly | Chief Financial Officer | 2024 | 461,000 | 191,776 | 1,222,005 | — | 18,606 | 1,893,387 |
| Michael Amoroso | Chief Executive Officer, President, Director | 2024 | 635,000 | 400,050 | 3,216,563 | — | 59,301 | 4,310,914 |
| Michael Amoroso | Chief Executive Officer, President, Director | 2023 | 629,917 | 381,000 | 967,976 | — | 60,388 | 2,039,280 |
| Alan List | Chief Medical Officer | 2023 | 475,721 | 191,200 | 217,800 | — | 25,250 | 909,970 |
| Alex Kelly | Chief Financial Officer | 2023 | 457,667 | 184,400 | 423,476 | — | 18,845 | 1,084,388 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 68 |
| 2024 | 108 |
| 2023 | 109 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 34,264,000 | 68,696,000 | 48,727,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 54,172,000 | 59,559,000 | 53,375,000 |
| General And Administrative Expenses | 32,240,000 | 35,299,000 | 39,088,000 |
| Operating Expenses | 86,412,000 | 94,858,000 | 92,463,000 |
| Operating Income | -52,148,000 | -26,162,000 | -43,736,000 |
| Net Income | -45,724,000 | 7,167,000 | -61,319,000 |
| Earnings Per Share Basic | -3.56 | 1.05 | -15.96 |
| Earnings Per Share Diluted | -3.56 | 1.04 | -15.96 |
| Weighted Average Shares Outstanding Basic | 12,826,078 | 6,832,982 | 3,841,405 |
| Weighted Average Shares Outstanding Diluted | 12,826,078 | 6,883,911 | 3,841,405 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 110,823,000 | 85,899,000 | 116,678,000 |
| Marketable Securities Current | 4,762,000 | 413,000 | — |
| Accounts Receivable | 0 | 229,000 | 901,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | 11,897,000 |
| Other Assets Current | 45,000 | 369,000 | 419,000 |
| Total Assets Current | 118,740,000 | 94,989,000 | 136,359,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 1,425,000 | 3,089,000 | 6,338,000 |
| Other Assets Non Current | 206,000 | 221,000 | 225,000 |
| Total Assets Non Current | 35,676,000 | 41,399,000 | 23,422,000 |
| Total Assets | 154,416,000 | 136,388,000 | 159,781,000 |
| Accounts Payable | 296,000 | 1,312,000 | 2,968,000 |
| Deferred Revenue | 0 | 2,957,000 | 12,035,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 649,000 | 989,000 | 2,391,000 |
| Total Liabilities Current | 8,913,000 | 14,980,000 | 49,987,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 259,000 | 194,000 | — |
| Total Liabilities Non Current | 53,255,000 | 65,015,000 | 90,933,000 |
| Total Liabilities | 62,168,000 | 79,995,000 | 140,920,000 |
| Common Stock | 1,000 | 1,000 | 1,000 |
| Retained Earnings | -528,188,000 | -482,464,000 | -489,631,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 92,248,000 | 56,393,000 | 18,861,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,468,000 | 3,404,000 | 6,817,000 |
| Share Based Compensation Expense | 10,186,000 | 12,604,000 | 14,040,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -229,000 | -672,000 | 181,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -737,000 | -2,096,000 | 1,508,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -65,843,000 | -58,445,000 | -84,114,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 85,000 | 250,000 | 1,957,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -634,000 | -215,000 | 5,829,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | 4,986,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 0 | 22,505,000 | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 95,162,000 | 50,450,000 | 5,387,000 |
| Change In Cash | 28,685,000 | -8,210,000 | -72,898,000 |
| Cash At End Of Period | 110,823,000 | 85,899,000 | 116,678,000 |
| Income Taxes Paid | 0 | — | — |
| Interest Paid | 1,355,000 | 1,738,000 | 2,018,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -3.56 | 1.05 | -15.96 |
| Price To Earnings Ratio | -1.1685 | 3.6286 | -0.6862 |
| Earnings Growth Rate | -439.0476 | -106.5789 | 1,156.6929 |
| Price Earnings To Growth Ratio | 0.0027 | -0.034 | -0.0006 |
| Book Value Per Share | 7.1922 | 8.2531 | 4.9099 |
| Price To Book Ratio | 0.5784 | 0.4616 | 2.2304 |
| Ebitda | -42,834,000 | 12,353,000 | -52,272,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -196,000 | 155,000 | -7,035,000 |
| Free Cash Flow | -65,647,000 | -58,600,000 | -77,079,000 |
| Return On Equity | -0.4957 | 0.1271 | -3.2511 |
| One Year Beta | 0.5506 | 0.4798 | 1.4992 |
| Three Year Beta | 0.7491 | 1.5488 | 1.7981 |
| Five Year Beta | 1.3295 | 1.4851 | 1.542 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| SMITH J. JEFFERSON | Chief Research Officer | 2026-02-18 | 4,925 | D | 121,926 |
| Scimeca Dario | General Counsel and Secretary | 2026-02-18 | 4,925 | D | 56,457 |
| Kelly John Alexander | Chief Financial Officer | 2026-02-18 | 8,149 | D | 125,883 |
| Amoroso Michael | Director, President and CEO | 2026-02-18 | 20,559 | D | 243,392 |
| SMITH J. JEFFERSON | Chief Research Officer | 2026-02-17 | 16,667 | A | 126,851 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Investors Research Corp | 2026-03-31 | 44 | 8 | 5.5 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 4,160 | 1,000 | 4.16 |
| Corient Private Wealth LLC | 2025-12-31 | 41,600 | 10,000 | 4.16 |
| NewEdge Advisors, LLC | 2025-12-31 | 90 | 22 | 4.0909 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 2025-12-31 | 52,250 | 12,560 | 4.16 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| DFA INVESTMENT DIMENSIONS GROUP INC | 2026-01-31 | U.S. SMALL CAP PORTFOLIO - INSTITUTIONAL CLASS | DFSTX | 853 | 3,377.88 | 0.0 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2026-01-31 | U.S. MICRO CAP PORTFOLIO - INSTITUTIONAL CLASS | DFSCX | 944 | 3,738.24 | 0.0001 |
| Dimensional ETF Trust | 2026-01-31 | Dimensional U.S. Small Cap ETF | DFAS | 6,455 | 25,561.8 | 0.0002 |
| Dimensional ETF Trust | 2026-01-31 | Dimensional U.S. Core Equity 2 ETF | DFAC | 3,162 | 12,521.52 | 0.0 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VITPX | 20,325 | 84,552 | 0.0003 |